- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03344913
Biologic Mechanisms for Pain Variation After Physical Activity in Osteoarthritis
Bioenergetics, Inflammation, and Protein Expression as Mechanisms for Variation in Pain Sensitivity After Physical Activity in Adults With Knee Osteoarthritis
Study Overview
Status
Intervention / Treatment
Detailed Description
Osteoarthritis (OA) in the knee is characterized by chronic inflammatory pain that is not necessarily associated with the amount of joint damage.1 Clinical practice guidelines recommend physical activity (PA) for osteoarthritis pain,2 but uptake of PA among adults with OA is very low.3 One reason for this is that while PA can reduce pain among adults with lower extremity OA,4,5 it does so differentially, decreasing pain sensitivity for about half of adults with OA but actually increasing pain sensitivity for the other half.6 Further, a recent meta-analysis revealed that engaging in a single type of PA (e.g. aerobic exercise or resistance training) reduces OA knee pain, but there was large heterogeneity in the results which could not be explained by age, sex, BMI, alignment in the knee, disease severity, or baseline pain.5 One of the goals of developing individualized PA interventions for adults with OA is to elucidate the mechanisms by which PA reduces OA pain and for whom PA most effectively diminishes the pain.
Aerobic physical activity, such as walking, increases cellular capacity for energy generation (ATP production) via oxidative phosphorylation up to 2-fold by stimulating mitochondrial biogenesis.7,8 This phenomenon occurs not only in skeletal muscle,7 but also in brain cells,9,10 liver cells,9,11,12 adipose tissue,13 kidney cells,12 and leukocytes14 indicating that PA likely increases metabolic demand systemically. Moreover, PA is thought to create adaptive changes in the activity and/or abundance of proteins involved in processes related to mitochondrial function.8 Mitochondrial function, including energy generation through oxidative phosphorylation; inflammation; and mitochondrial related protein expression are key features in osteoarthritis15,16 and chronic inflammatory pain.17,18 Animal models of inflammatory pain demonstrate a cellular metabolic shift from oxidative phosphorylation to glycolysis in chronic inflammatory states via the pyruvate dehydrogenase kinase 2/4 (PKD2/4)-pyruvate dehydrogenase (PDH)-lactic acid axis.19 This results in an increase in lactic acid production in the affected area. The ensuing acidic microenvironment amplifies the nociceptive response via recruitment of additional pro-algesic proinflammatory cytokines which "activate nociceptors and spinal glia to cause peripheral and central sensitizations, respectively".19 Thus, improvement in the capacity to generate ATP through oxidative phosphorylation, and associated reduction of glycolysis, may reduce pain sensitivity. However, while a large body of animal and correlational data supports a strong link between oxidative potential and pain outcomes, experimental evidence of cause and effect remains sparse, especially in humans.8
The investigators are hypothesizing that individual differences in systemic cellular bioenergetic function, inflammation, and protein expression influence the effect of PA to reduce pain sensitivity in adults with knee OA. The purpose of this quasi-experimental pilot study is to test mitochondrial bioenergetics (oxidative phosphorylation, mitochondrial content) in platelets, inflammation (cytokines) and protein expression as mechanisms for variation in pain sensitivity immediately after 30 minutes of walking (i.e. "acute") and after six weeks of walking three times a week for 30 minutes (i.e. "long-term") in adults with knee osteoarthritis. The investigators will address the following specific aims and hypotheses in a sample of 40 adults with radiologic evidence of hip or knee OA and 20 age/gender matched healthy controls:
Aim 1: To examine the effects of a six week (three days/week) walking program on pain thresholds in adults with knee OA as compared to healthy controls H1.1: Pain sensitivity (Quantitative Sensory Testing) will increase in approximately 50% of adults with OA and decrease in approximately 50% of adults with OA after acute and long-term PA.
H1.2: Pain sensitivity will decrease in healthy controls after acute and long-term PA.
Aim2: To test the role of mitochondrial bioenergetics (oxidative phosphorylation, mitochondrial content) as a mechanism for variation in pain sensitivity after PA in older adults with knee OA.
H2.1: Pain sensitivity is negatively associated with mitochondrial function (oxidative phosphorylation, mitochondrial content) in platelets at baseline, after acute PA and long-term PA H2.2: Healthy controls will have higher capacity for oxidative phosphorylation in platelets than OA participants.
Aim3: To test the role of inflammation as a mechanism for variation in pain sensitivity after physical activity in older adults with knee OA.
H3.1: Pain sensitivity is positively associated with increased circulating proinflammatory cytokines (c-reactive protein, interleukin (IL)-1, IL-1β, IL-6, IL-10, tumor necrosis factor (TNF)-α, PGES) at baseline, after acute and long-term PA.
Aim 4: To generate hypotheses regarding the role of proteomics in variation in pain sensitivity after physical activity (immediacy following and after six weeks of walking program) Changes in protein expression will depend on the half-life of the protein being expressed which can range from minutes to days.8 Thus, it is important to examine adaptive changes in protein expression in both the short (minutes/day post PA) and long term (days/weeks between bouts of physical activity).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland, Baltimore
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Adults with Osteoarthritis:
- Age 50-80
- radiographic evidence of knee osteoarthritis (OA participants)
- self-report current non-smoker
- willing and able to walk for 30 minutes a day three days a week for six weeks at a location that is within 30 minutes from University of Maryland Baltimore
- speaks English
Healthy Controls:
- Age 50-80
- self-reports no osteoarthritis
- self-report current non-smoker
- willing and able to walk for 30 minutes a day three days a week for six weeks at a location that is within 30 minutes from University of Maryland Baltimore
- speaks English
Exclusion Criteria:
- unable to pass the evaluation to sign consent
- diagnosis of rheumatoid arthritis
- diagnosis of gout
- diagnosis of heart failure
- diagnosis of chronic obstructive pulmonary disease
- diagnosis of diabetes
- diagnosis of Parkinson's disease
- diagnosis of Alzheimer's disease
- diagnosis of autoimmune disease
- currently taking long-term steroid medications such as methotrexate
- weight less than 110 lbs.
- direct employee of the PI
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Adults with knee Osteoarthritis
walking 30 minutes per day, three days/week for 6 weeks.
|
walking 30 minutes per day, three days/week for 6 weeks with a member of study team.
|
|
Active Comparator: Healthy controls
walking 30 minutes per day, three days/week for 6 weeks.
|
walking 30 minutes per day, three days/week for 6 weeks with a member of study team.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain sensitivity
Time Frame: Baseline and immediately after 30 minutes of walking
|
Change from baseline pain threshold/tolerance after 30 minutes of walking
|
Baseline and immediately after 30 minutes of walking
|
|
Pain sensitivity
Time Frame: Baseline and within 4 weeks after completing six weeks of walking for 30 minutes three days/week
|
Change from baseline pain threshold/tolerance after six weeks of walking for 30 minutes three days/week
|
Baseline and within 4 weeks after completing six weeks of walking for 30 minutes three days/week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
platelet mitochondrial function
Time Frame: immediately after 30 minutes of walking
|
platelet oxygen consumption as indicator of cellular energy production via oxidative phosphorylation or glycolysis; mitochondrial copy number; mitochondrial proteins
|
immediately after 30 minutes of walking
|
|
platelet mitochondrial function
Time Frame: after six weeks of walking for 30 minutes
|
platelet oxygen consumption as indicator of cellular energy production via oxidative phosphorylation or glycolysis; mitochondrial copy number; mitochondrial proteins
|
after six weeks of walking for 30 minutes
|
|
Inflammatory markers in plasma
Time Frame: immediately after 30 minutes of walking
|
c-reactive protein (CRP), Interleukin (IL)-1, IL-1β, IL-6, IL-10, Tumor Necrosis factor-alpha (TNF-α), prostaglandin-e (PGES)
|
immediately after 30 minutes of walking
|
|
Inflammatory markers in plasma
Time Frame: after six weeks of walking for 30 minutes
|
c-reactive protein (CRP), Interleukin (IL)-1, IL-1β, IL-6, IL-10, Tumor Necrosis factor-alpha (TNF-α), prostaglandin-e (PGES)
|
after six weeks of walking for 30 minutes
|
|
Platelet protein signatures
Time Frame: immediately after 30 minutes of walking
|
Platelet protein signatures will be explored using nanocapillary liquid chromatography-mass spectrometry (LC-MS/MS) coupled to an Orbitrap MS that combines two mass analyzers to allow simultaneous precursor ion scans from which relative quantitative data is derived between two groups (hi and low pain groups) and fragmentation data from which peptide sequence matches are made.
|
immediately after 30 minutes of walking
|
|
Platelet protein signatures
Time Frame: after six weeks of walking for 30 minutes
|
Platelet protein signatures will be explored using nanocapillary liquid chromatography-mass spectrometry (LC-MS/MS) coupled to an Orbitrap MS that combines two mass analyzers to allow simultaneous precursor ion scans from which relative quantitative data is derived between two groups (hi and low pain groups) and fragmentation data from which peptide sequence matches are made.
|
after six weeks of walking for 30 minutes
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jennifer Klinedinst, PhD, University of Maryland, Baltimore
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HP-00076861
- 1P30NR016579-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
Boston Scientific CorporationRecruitingLow Back Pain | Chronic Pain | Chronic Low-back Pain | Leg Pain | Intractable Pain | Chronic Leg PainUnited States
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Qi's ClinicNot yet recruitingNon-Cancer Pain,Musculoskeletal Pain,Chronic Pain,Acute Pain
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
noiVita SrlsUniversity of Eastern PiedmontCompletedCervical Pain | Pain Management | Lumbar Pain | Muscular | Chronic Pain (Back / Neck)Italy
-
Chinese University of Hong KongNot yet recruitingPain, Acute | Chronic Post Operative Pain | Pain, ChronicHong Kong
-
University of SaskatchewanRoyal University Hospital FoundationCompletedPain | Pain, Acute | Pain, Chronic | Pain, IntractableCanada
-
Kyowa Kirin Co., Ltd.Completed
Clinical Trials on Walking
-
Beijing Chao Yang HospitalPeking University First Hospital; Guang'anmen Hospital of China Academy of... and other collaboratorsUnknownInflammation | COPDChina
-
State University of New York at BuffaloCompletedFatigue | ExerciseUnited States
-
National Defense Medical Center, TaiwanMinistry of Science and Technology, TaiwanCompletedExercise | Happiness | Educational Problems
-
Pacific Northwest University of Health SciencesTerminatedParkinson DiseaseUnited States
-
Istanbul Medipol University HospitalCompleted
-
University of NebraskaNational Institute of General Medical Sciences (NIGMS)CompletedOlder Adults | Fall PatientsUnited States
-
East Tennessee State UniversityRecruitingPARKINSON DISEASE (Disorder)United States
-
Acibadem UniversityRecruitingPulmonary Disease, Chronic ObstructiveTurkey
-
Pamukkale UniversityCompleted
-
Chulalongkorn UniversityCompleted